Adaptyv
Automated, AI-native wet labs for testing and validating computationally designed proteins.
Website: https://www.adaptyvbio.com/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Adaptyv |
| Tagline | Automated, AI-native wet labs for testing and validating computationally designed proteins [adaptyvbio.com] |
| Headquarters | Lausanne, Switzerland [Crunchbase] |
| Founded | 2021 [Crunchbase] |
| Stage | Series A [Wowtale, August 2026] |
| Business model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) [Wowtale, August 2026] |
| Funding label | $50M+ |
| Total disclosed | Approximately $42,500,000 [Wowtale, August 2026] |
Links
PUBLIC
- Website: https://www.adaptyvbio.com/
- LinkedIn: https://ch.linkedin.com/company/adaptyvbio
The Short Version
PUBLIC Adaptyv builds automated, AI-native wet labs that turn digital protein sequences into experimental validation data, and it merits attention now because the company has moved from concept framing to a reported €34.35 million, approximately $40 million, Series A while positioning itself at a real bottleneck in AI-driven protein design: wet-lab validation capacity [adaptyvbio.com] [ycombinator.com] [Wowtale, August 2026]. Founded in Lausanne in 2021, the company traces back to an EPFL connection between co-founders Julian Englert and Daniel Nakhaee-Zadeh Gutierrez, with public profiles and later coverage also tying Moustafa Houmani and Amir Shahein to the founding team [adaptyvbio.com] [artificialatlas.org] [Wowtale, August 2026].
The product case is straightforward: Adaptyv automates the experimental layer for protein-design teams that can generate candidates computationally but do not want to build equivalent in-house lab infrastructure, and public materials suggest the platform now extends through an API integrated with tools such as Benchling, Cradle, Boltz, Chai, Tamarind, and Latent Labs [ycombinator.com] [Ventureburn] [LeadIQ]. That differentiation is still best read cautiously because much of the technical positioning remains company-described, but there is at least some external support for operational usage, including reports that the platform has tested more than 10,000 proteins with over 30 pharma and biotech teams since beta launch [BioAlps] [LinkedIn].
The founding team appears technically credible for this problem set. Englert is publicly identified as co-founder and CEO, while YC and other profiles describe Daniel Nakhaee-Zadeh Gutierrez as a co-founder with experience spanning immunoengineering, synthetic biology, and computational biology across EPFL, Harvard, Leeds, KAIST, AlveoliX, and iGEM [Julian Englert - LinkedIn, Retrieved 2026] [ycombinator.com] [The Org].
On financing, the public record supports a venture-scale path: early backing from Wingman Ventures, an $8 million seed led by ACE Ventures in November 2024, and the August 2026 Series A led by Highland Europe, with byFounders and Y Combinator also named as investors [Wowtale, August 2026] [venturecapitaltracker.com]. The business model is B2B by customer profile and workflow, but the next 12 to 18 months will matter less on narrative and more on evidence of repeatable commercial adoption, specifically whether Adaptyv can translate reported customer breadth, throughput growth, and API integrations into durable enterprise relationships with protein-design teams and larger pharma buyers [Dealroom News] [GGBa] [adaptyvbio.com].
Unconfirmed -- The section relies on a mix of company materials, startup databases, LinkedIn profiles, and one reported financing article; several material product and traction claims remain company-originated or lightly corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $50M+ total disclosed, approximately $42.5M |
The Company in Brief
From the public record Adaptyv sits in a part of biotech where software progress has outpaced lab capacity. The company describes itself as a Lausanne-based business founded in 2021, building automated wet-lab infrastructure for testing computationally designed proteins, while Crunchbase lists the entity as Adaptyv Biosystems in Lausanne, Switzerland [adaptyvbio.com] [Crunchbase].
The founding record is directionally consistent across the company website and startup databases, even if the public role map is not perfectly settled. Adaptyv’s team page identifies Julian Englert as co-founder and CEO and says he met Daniel Nakhaee-Zadeh Gutierrez at EPFL before starting the company in 2021, while Crunchbase records the company as founded in 2021 and based in Lausanne [adaptyvbio.com] [Crunchbase].
The public milestone trail is still fairly short, which is typical for a company at this stage. Crunchbase shows Adaptyv Biosystems as a venture-backed startup, and the company website positions the business around turning digital protein sequences into experimental validation workflows, suggesting the core operating thesis has been consistent from founding through its current growth phase [Crunchbase] [adaptyvbio.com].
Single-source, plausible -- Confirmed primarily by the company website and Crunchbase, with founding date and headquarters corroborated but limited legal-entity detail in the cited public record.
What They Have Built
Core platform
MIXED The technical claim worth anchoring on is straightforward: Adaptyv says its platform takes a digital protein sequence and returns experimental validation data through automated wet-lab workflows [adaptyvbio.com]. That positioning is consistent across the company site and Y Combinator profile, which describe Adaptyv as infrastructure for protein-design teams that want to test more candidates without standing up equivalent in-house lab capacity [adaptyvbio.com] [Y Combinator]. Public descriptions also point to an automated cloud-lab or wet-lab model rather than software-only tooling, with references to robotics, microfluidics, synthetic biology, and parallel protein measurement appearing in company and ecosystem materials [startupticker.ch] [Biopôle] [Heinz Gärtner - LinkedIn, Retrieved 2026].
The more concrete proof points are still partly company-led. Adaptyv has publicly associated itself with DNA synthesis brought in-house, cell-free protein expression, and an API layer that connects with tools including Benchling, Boltz, Chai, Cradle, Tamarind, and Latent Labs, according to startup coverage and company-adjacent writeups [Wowtale, August 2026] [Ventureburn] [LeadIQ] [Konsulteer]. Those claims fit the stated workflow thesis, namely that the product is meant to close the gap between computational protein design and empirical lab readout, but the underlying performance, reproducibility, and economics of the stack are not described in enough public detail to verify independently [adaptyvbio.com] [Y Combinator].
Evidence of use
MIXED Public usage signals are stronger than the technical disclosures, although they remain uneven by source quality. Company materials and related profiles indicate that Adaptyv has tested more than 10,000 proteins with more than 30 pharma and biotech teams since beta launch, and several sources repeat a reported improvement in success rates from 2.5% to 13% over two months [BioAlps] [LinkedIn, Retrieved 2026] [Reto Gurtner - LinkedIn, Retrieved 2026] [Adrien Jacquier - LinkedIn, Retrieved 2026]. The company site also names organizations such as MIT, Microsoft, Chai Discovery, Cradle, and Boltz in connection with its platform, while other public references add Roche and Novo Nordisk to the customer list [adaptyvbio.com] [GGBa].
There is enough public evidence to conclude that the product is in live external use, and that Adaptyv is selling a lab-service-plus-software interface rather than a research concept alone [adaptyvbio.com] [Y Combinator] [BioAlps]. The main analytical constraint is that many of the most interesting product claims, especially customer count, workflow integrations, and biological hit-rate improvement, are still derived from company statements, partner posts, or startup ecosystem summaries rather than detailed third-party validation [Wowtale, August 2026] [Dealroom News] [GGBa].
Unconfirmed -- Core product description is corroborated by company and Y Combinator sources, but several material technical and performance claims remain company-led or only partially corroborated by ecosystem and LinkedIn sources.
Market Size and Demand
Market context
PUBLIC The market matters now because protein design capacity appears to be scaling faster than wet-lab validation capacity, and Adaptyv is positioned at that bottleneck rather than at the model layer itself [ycombinator.com] [adaptyvbio.com]. Public materials consistently describe the company as an automated lab for testing computationally designed proteins, which places it inside a convergence zone between synthetic biology infrastructure, contract research workflows, and AI-enabled drug discovery rather than a single clean market category [ycombinator.com] [Biopôle] [startupticker.ch]. That framing is important for sizing: the available source set does not include a named third-party TAM study for Adaptyv’s exact segment, so any market view here has to be built from adjacent demand signals rather than asserted as a hard revenue pool.
The clearest demand signal in the public record is that customers appear to include both AI-first biology teams and established enterprise buyers. Company materials name MIT, Microsoft, Chai Discovery, Cradle, and Boltz as users or customers, while third-party coverage reports more than 30 pharma and biotech teams and over 10,000 proteins tested since beta launch [adaptyvbio.com] [BioAlps] [LinkedIn, Retrieved 2026]. A separate public claim says Adaptyv has onboarded over 100 customers, including Roche and Novo Nordisk, though that claim rests on startup ecosystem coverage rather than primary customer confirmation and should be treated with some care [GGBa].
These signals suggest the initial serviceable market is not "all biotech R&D," but a narrower budget line: teams that generate protein candidates computationally and need fast experimental readouts without building internal automated wet labs. That buyer set plausibly spans frontier AI labs, biotech startups, academic translational groups, and large pharmaceutical R&D teams, according to company and third-party descriptions [ycombinator.com] [Wowtale, August 2026] [adaptyvbio.com]. The practical implication is that adoption may track the growth of protein design workflows more closely than broader life sciences spending.
| Market lens | Public evidence | Reading |
|---|---|---|
| Core market | Automated wet-lab validation for computational protein design [ycombinator.com] [adaptyvbio.com] | Narrower than general CRO or lab automation |
| Adjacent market | AI-native drug discovery and protein engineering tooling [Biopôle] [startupticker.ch] | Customer budgets may come from discovery platforms and R&D enablement |
| Substitute market | In-house lab automation and outsourced biology services [ycombinator.com] | Main substitute is internal build or traditional wet-lab outsourcing |
| Expansion surface | API-linked software and workflow integrations with tools such as Benchling, Chai, Cradle, Boltz, Tamarind, and Latent Labs [Ventureburn] [LeadIQ] [Konsulteer] | Suggests workflow embedment beyond pure lab capacity |
The table points to a market definition that is workflow-specific rather than sector-wide. For investors, that usually means the near-term opportunity depends less on abstract biotech TAM and more on whether computational design teams increasingly treat validation throughput as a purchased infrastructure layer.
Demand drivers and adjacent markets
PUBLIC The strongest tailwind is the widening gap between software-side design speed and experiment-side validation speed. Adaptyv’s own positioning is explicit that AI can generate protein candidates faster than many teams can test them, and Y Combinator’s company description supports the same bottleneck thesis from an external platform perspective [adaptyvbio.com] [ycombinator.com]. If that bottleneck is real across the category, demand should be driven by cycle time reduction, not only by absolute biology spend.
Public traction claims, while partly company-originated, also point in that direction. BioAlps and LinkedIn-sourced descriptions report that the platform has tested over 10,000 proteins with more than 30 pharma and biotech teams since beta, and that success rates improved from 2.5% to 13% over two months in cited examples [BioAlps] [LinkedIn, Retrieved 2026] [Adrien Jacquier - LinkedIn, Retrieved 2026]. Those figures are not enough to establish a category benchmark, but they do suggest that buyers may value Adaptyv on throughput and feedback-loop compression rather than on a conventional outsourced-services model alone.
A second tailwind is the rise of connected software and model ecosystems around biology. Multiple public sources state that Adaptyv’s API is integrated with Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling [Ventureburn] [LeadIQ] [Konsulteer]. If accurate, that matters because it implies the company could sit in the execution layer of a broader computational biology toolchain, where switching costs may come from workflow integration and data continuity as much as from physical lab capacity.
The adjacent markets are also clear enough from the source set. One is lab automation, where robotics and microfluidics are described as core technical ingredients [startupticker.ch] [Amir Shahein - LinkedIn, Retrieved 2026]. Another is synthetic biology infrastructure, where buyers need synthesis, expression, and measurement capacity in parallel [Biopôle] [AI Market Watch]. A third is contract research and specialized assay services, which remain functional substitutes for teams unwilling to build internal wet-lab systems [ycombinator.com].
Regulatory and macro considerations
PUBLIC This is a market with meaningful macro support, but also with procurement and regulatory friction that can slow adoption. The support comes from sustained investor interest in AI-enabled biology infrastructure, reflected in Adaptyv’s financing path from pre-seed through a reported $40 million Series A led by Highland Europe in August 2026 [Wowtale, August 2026] [venturecapitaltracker.com]. While a funding round does not prove end-market depth, it does show that capital is available for platforms promising to compress design-to-validation cycles in biotech.
On regulation, the available public sources do not document a specific FDA, EMA, or CLIA pathway for Adaptyv itself, and that absence matters. The company appears to sell research infrastructure rather than a therapeutic product, which generally places the immediate compliance burden more on lab operations, data handling, biosafety, and customer quality requirements than on direct drug approval exposure, based on the product descriptions in the source set [adaptyvbio.com] [Biopôle] [startupticker.ch]. Even so, customers in pharma and translational research are likely to care about reproducibility, auditability, and data provenance, especially if Adaptyv aims to become part of regulated development workflows.
Macro conditions cut both ways. On one hand, buyers are under pressure to shorten R&D cycles and extract more signal from fewer experiments, which supports automation vendors and outsourced lab platforms [ycombinator.com] [Wowtale, August 2026]. On the other, biotech budget cycles remain uneven, and capital-intensive lab businesses usually face a slower scaling profile than software-only tools because physical throughput, instrumentation uptime, and site expansion can become constraints before demand does.
What the public evidence supports, then, is not a broad claim that this market is already proven at scale, but a narrower one: the category sits where several durable budgets intersect, and the need it addresses appears increasingly concrete as protein design software improves. The market question is less whether computational biology will grow, and more whether enough teams prefer a shared automated validation layer over building comparable lab capacity themselves [ycombinator.com] [adaptyvbio.com].
Single-source, plausible -- Section relies on company materials, YC profile, and third-party ecosystem coverage; no named third-party TAM report or independent market-size dataset was available in the provided sources.
Who Else Is Fighting for This
Competitive positioning
MIXED Adaptyv is competing less against a single named startup peer than against a stack of alternatives: internal wet labs at pharma and biotech companies, contract research workflows, and the growing set of software tools that can design proteins faster than most labs can validate them [adaptyvbio.com] [ycombinator.com].
The segment map is unusually asymmetric because the company sits between software-native protein design and physical experimentation. On one side are incumbents, meaning large pharmaceutical and biotech organizations that already operate in-house protein engineering and validation infrastructure, and therefore have the option to keep testing internal rather than outsource or route workflows through an external platform [ycombinator.com] [Wowtale, August 2026]. On another side are adjacent substitutes: computational design tools and model providers such as Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling integrations, which help create or manage candidate proteins but do not by themselves establish wet-lab truth, at least from the evidence available here [Wowtale, August 2026] [Ventureburn]. That leaves Adaptyv trying to occupy the narrow but consequential layer where digital sequences become experimental data.
The clearest edge visible in public materials is workflow position rather than category ownership. The company describes a platform that starts with a digital protein sequence and returns experimental validation data through automated lab workflows, and multiple sources indicate the API is already integrated with design and lab software used by AI-native biology teams [adaptyvbio.com] [Wowtale, August 2026] [Ventureburn]. If those integrations are active in customer workflows, Adaptyv may benefit from being inserted early in the design-test loop, which can make switching costly once teams build protocols, data formats, and iteration cycles around a single external lab partner. That said, the durability of this edge is still uncertain because the evidence is strongest for integration breadth and customer count claims, not for renewal behavior, contract depth, or exclusive data assets [Wowtale, August 2026] [BioAlps].
The company also appears to have some operating use in throughput and infrastructure buildout, although public evidence is mixed on how proprietary that advantage is. Adaptyv has reported testing more than 10,000 proteins with over 30 pharma and biotech teams, and Dealroom-linked coverage says throughput grew more than 5x over the past year [BioAlps] [Dealroom News]. Bringing DNA synthesis in-house, as reported in 2026 coverage, could improve cycle time and reduce dependency on third parties if true at production scale [Wowtale, August 2026]. Still, this looks perishable rather than permanent: well-capitalized customers can expand internal automation, and other service or platform providers can replicate parts of the workflow if the demand pool proves large enough.
The main exposure is that Adaptyv does not appear to own the upstream design layer or the downstream therapeutic asset economics. Public sources name integrations with Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling, which suggests the company is intentionally interoperable rather than vertically dominant [Wowtale, August 2026] [LeadIQ]. Interoperability can help distribution, but it also means those software surfaces retain the user relationship and could influence routing decisions if they expand into validation partnerships or proprietary lab access. Internal pharma labs are the other obvious pressure point: for large buyers, external validation is attractive when speed and flexibility matter, but the largest accounts may still prefer to keep sensitive workflows, assay development, and scale economics in house if utilization justifies the capital spend [ycombinator.com] [Wowtale, August 2026].
Over the next 18 months, the most plausible competitive outcome is not winner-take-all but workflow consolidation around a handful of design-to-validation stacks. Winner if X: Benchling, if platform buyers continue to prefer orchestration layers that sit above multiple experimental providers, because control of system-of-record software can shape vendor access without owning the wet lab itself [Ventureburn] [Konsulteer]. Loser if Y: internal pharma wet labs, if external automated validation keeps improving cycle time and success-rate outcomes enough to make fixed internal capacity look slower or less flexible for exploratory programs, though the current success-rate evidence still comes from limited public reporting and company-linked channels [LinkedIn] [Reto Gurtner - LinkedIn]. For Adaptyv specifically, the competitive question is whether it becomes the default execution layer for AI-designed proteins, or remains one of several interchangeable validation endpoints inside someone else’s workflow.
Opportunity
Upside path
PUBLIC The prize here is unusually large because Adaptyv is trying to become the missing physical layer for AI-designed proteins, the lab system that turns model output into experimental truth fast enough for software-like iteration cycles [adaptyvbio.com] [ycombinator.com].
The headline opportunity is not simply contract lab revenue. If Adaptyv can sit between computational protein design and validation at scale, it could become default infrastructure for teams that can generate candidate sequences far faster than they can test them internally [ycombinator.com] [adaptyvbio.com]. That outcome looks reachable, rather than purely aspirational, because the public record already shows three ingredients that usually matter in platform formation: the company says it has tested more than 10,000 proteins with more than 30 pharma and biotech teams, it reports a meaningful improvement in success rates from 2.5% to 13% over two months, and it has shipped a public API that outside tools can connect to [BioAlps] [Adrien Jacquier - LinkedIn] [Ventureburn]. None of that proves durable market leadership, but it does suggest Adaptyv is moving beyond a concept-stage automation story into an operating system for experimental iteration.
A second reason the upside is material is customer breadth. Public claims place Adaptyv at more than 100 customers, with named organizations on company materials including MIT, Microsoft, Chai Discovery, Cradle, and Boltz, and third-party reports naming Roche and Novo Nordisk among customers [adaptyvbio.com] [Wowtale, August 2026] [GGBa]. In biotech infrastructure, breadth can matter as much as depth early on, because the winning lab platform often becomes the default place to send the next workflow once trust is established.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| API layer for protein design | Adaptyv becomes the standard validation endpoint used by AI protein design tools, with customers sending candidate sequences directly from software into automated wet-lab workflows | Wider adoption of Adaptyv's public API and deeper integrations with tools such as Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling [Ventureburn] [Konsulteer] | The company is already described as running a public API integrated with multiple design and workflow tools, which is the clearest public sign that it wants software distribution rather than one-off service work [Ventureburn] [LeadIQ] |
| Trusted foundry for frontier biology teams | Adaptyv becomes an externalized experimental engine for AI-native drug discovery groups, frontier AI labs, and large pharma teams that want speed without building equivalent in-house automation | A category-tipping set of reference customers and repeat usage from pharma and biotech teams [BioAlps] [GGBa] | Public sources already describe more than 30 pharma and biotech teams using the platform and cite named customers across research institutions, software-native biology companies, and reported pharma buyers [BioAlps] [adaptyvbio.com] [GGBa] |
| Closed-loop discovery platform | Adaptyv moves from validation infrastructure into a learning system where experimental outputs improve future design decisions, raising customer switching costs | Continued throughput growth and collaborations such as the Claude-based workflow with Anthropic for selecting designs for wet-lab testing [Proteinbase, 2026] [Dealroom News] | The company says throughput grew more than 5x over the past year, and the Anthropic workflow points to a future in which model selection and lab validation are increasingly linked [Dealroom News] [Proteinbase, 2026] |
The compounding mechanism is straightforward. Every additional customer and protein tested can improve the company's understanding of which designs fail, which assays matter, and how to route workflows through automation, assuming Adaptyv retains and structures that experimental output effectively [adaptyvbio.com] [BioAlps]. The early signs of this flywheel are visible in public claims: more than 10,000 proteins tested, more than 30 pharma and biotech teams on the platform, throughput growth of more than 5x over the past year, and API integrations that can bring more designs into the lab without equivalent customer-side overhead [BioAlps] [Dealroom News] [Ventureburn]. If that loop tightens, Adaptyv's value shifts from selling access to equipment toward owning a high-frequency validation layer that gets better as the market scales.
The size of the win is hard to anchor precisely because no public market comparable in the provided source set offers a clean market-cap reference. Even so, the latest disclosed Series A of about $40 million, led by Highland Europe, indicates investors see room for a much larger infrastructure outcome than a niche services business [Wowtale, August 2026] [venturecapitaltracker.com]. A reasonable upside frame is that if the "API layer for protein design" scenario plays out and Adaptyv becomes embedded across the leading AI-protein toolchain, the company could support platform-style economics and strategic value far above a conventional lab vendor, potentially reaching multi-billion-dollar enterprise value over time (scenario, not a forecast). That statement rests on role and positioning, not on a published revenue multiple, so it should be read as an upper-bound strategic outcome rather than a model output.
Inferred, not confirmed -- Core upside logic uses a mix of company claims, LinkedIn-based operating metrics, and third-party startup coverage; several material premises, including customer count and API breadth, are not independently verified by two public sources.
Sources
From the public record
[adaptyvbio.com] Adaptyv | https://www.adaptyvbio.com/
[Crunchbase] Adaptyv Biosystems - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/adaptyv-biosystems
[Wowtale, August 2026] Adaptyv Bio Raises $40M to Automate the Lab That Validates AI-Designed Proteins | https://en.wowtale.net/2026/08/29/234934
[ycombinator.com] Adaptyv | https://www.ycombinator.com/companies/adaptyv
[artificialatlas.org] Julian Englert - Co-Founder and CEO @ Adaptyv Biosystems | https://www.artificialatlas.org/person/julian-englert/
[Julian Englert - LinkedIn, Retrieved 2026] Julian Englert | https://www.linkedin.com/in/julian-englert/
[The Org] Daniel Nakhaee-Zadeh Gutierrez | https://theorg.com/org/adaptyv-biosystems/org-chart/daniel-nakhaee-zadeh-gutierrez
[venturecapitaltracker.com] Adaptyv Funding, Valuation & Investors | https://venturecapitaltracker.com/startup/adaptyv
[Ventureburn] Adaptyv Bio raises $40m to automate protein validation for AI-designed drugs | https://ventureburn.com/2026/08/adaptyv-bio-raises-40m-to-automate-protein-validation/
[LeadIQ] Adaptyv Bio raises $40M to automate the lab that validates AI-designed proteins | https://leadiq.com/c/wowtale/66cfd6464456a046c2529fd6
[BioAlps] Adaptyv Bio raises $40M to automate the lab that validates AI-designed proteins | https://www.bioalps.org/adaptyv-bio-raises-40m-to-automate-the-lab-that-validates-ai-designed-proteins/
[LinkedIn, Retrieved 2026] Adaptyv Bio | LinkedIn | https://ch.linkedin.com/company/adaptyvbio
[startupticker.ch] Adaptyv Bio wins Venture Kick and launches protein foundry | https://www.startupticker.ch/en/news/adaptyv-bio-wins-venture-kick-and-launches-protein-foundry
[Biopôle] Adaptyv Biosystems | https://www.biopole.ch/company/adaptyv-biosystems/
[Heinz Gärtner - LinkedIn, Retrieved 2026] Heinz Gärtner | https://www.linkedin.com/in/heinzgaertner/
[Konsulteer] Adaptyv Bio raises $40M to automate the lab that validates AI-designed proteins | https://www.konsulteer.com/adaptyv-bio-raises-40m-to-automate-the-lab-that-validates-ai-designed-proteins/
[Reto Gurtner - LinkedIn, Retrieved 2026] Reto Gurtner | https://www.linkedin.com/in/reto-gurtner/
[Adrien Jacquier - LinkedIn, Retrieved 2026] Adrien Jacquier | https://www.linkedin.com/in/adrien-jacquier/
[Dealroom News] Adaptyv Bio raises $40M to automate the lab that validates AI-designed proteins | https://dealroom.co/companies/adaptyv_bio/news
[GGBa] Adaptyv Bio raises $40M to automate the lab that validates AI-designed proteins | https://ggba.swiss/en/adaptyv-bio-raises-40m-to-automate-the-lab-that-validates-ai-designed-proteins/
[Amir Shahein - LinkedIn, Retrieved 2026] Amir Shahein | https://www.linkedin.com/in/amir-shahein/
Articles about Adaptyv
- A Swiss Startup Is Building a Protein Printer for AI Labs — The Swiss deeptech startup, backed by Highland Europe, turns digital protein designs into experimental validation data for over 100 customers.